Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2024 Nov 27;25(1):429.
doi: 10.1186/s12882-024-03868-5.

Proteinuria following administration of immune check point inhibitor: a case-control observational study

Jianan Su #  1   2 , Zhuofei Bi #  2   3 , Pengwei Chen  1   2 , Ziqing Gao  1   2 , Qiongqiong Yang  4   5 , Min Feng  6   7
Affiliations
Observational Study

Proteinuria following administration of immune check point inhibitor: a case-control observational study

Jianan Su et al. BMC Nephrol. .

Abstract

Purpose: Proteinuria during treatment of immune checkpoint inhibitors (ICIs) was another renal adverse event besides from acute kidney injury. We aim to investigate the incidence and associated factors of proteinuria associated with ICIs.

Method: A case-control observational study about ICIs-treated cancer patients was conducted. Clinical and laboratory data at the baseline and during the follow-up was collected. Patients developed proteinuria during ICIs-treatment were classified to the proteinuria group.

Results: Between March 2019 and August 2022, 440 patients were included in the study. Forty-eight patients (10.9%) developed proteinuria after ICIs-treatment. The occurrence of acute kidney injury between the proteinuria group and the control showed no difference[1(2.1%) vs. 9(2.3%), p = 1.000]. By multivariable logistic analysis, accumulative cycle of ICIs-administration (OR 1.079, 95% CI 1.033 to 1.127, p = 0.001) and comorbidity of liver cirrhosis (OR 2.198, 95% CI 1.082 to 4.468, p = 0.030) were associated with occurrence of proteinuria after ICIs-treatment independently.

Conclusions: Proteinuria could develop during the course of ICIs-therapy. Urinalysis should be monitored, especially for patients received multi-cycle of ICIs-administration and comorbid with liver cirrhosis.

Keywords: Immune checkpoint inhibitor; Liver cirrhosis; Multivariate analysis; Proteinuria.

PubMed Disclaimer

Conflict of interest statement

Declarations. Ethics approval and consent to participate: The study had received approval from the Ethics Review Board of Sun Yat-sen Memorial Hospital (Approval Number: SYSEC-KY-KS-2021-057). Due to the retrospective nature of the study, the Ethics Review Board of Sun Yat-sen Memorial Hospital waived the requirement for informed consent(Approval Number: SYSEC-KY-KS-2021-057). Consent for publication: Not applicable. Conflict of interest: All authors declare that they have no conflict of interest.

References

    1. Kitchlu A, Jhaveri KD, Wadhwaniet S. A systematic review of Immune Checkpoint inhibitor-Associated glomerular disease. Kidney Int Rep. 2021;6(1):66–77. - PMC - PubMed
    1. Webster AC, Nagler EV, Mortonet RL. Al Chronic Kidney Disease Lancet. 2017;389(10075):1238–52. - PubMed
    1. Xu LY, Zhao HY, Yuet XJ. al., Clinicopathological features of kidney Injury related to Immune checkpoint inhibitors: a systematic review. J Clin Med. 12 (4) (2023). - PMC - PubMed
    1. Kidney Disease. Improving global outcomes (KDIGO) CKD Work Group, KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl. (2013) 1–150.
    1. National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0. 2017; https://ctep.cancer.gov/protocoldevelopment/electronic_applications/ctc....

Publication types

Substances

LinkOut - more resources